Anti-obesity effect of Neoagaro-oligosaccharides with overweight and obese subjects: a 16-week, randomized, double-blind, placebo-controlled clinical trial
Background This trial aimed to evaluate the anti-obesity effects and safety of Neoagaro-oligosaccharides (NAOs) in humans in a 16 week, randomized, double-blind, placebo-controlled clinical trial. Methods One hundred overweight or obese subjects with a body mass index of 23 to 34.9 kg/$ m^{2} $ and a percent body fat of > 25% for males or > 30% for females were enrolled. NAOs or placebo products were administered at 3 g (twice a day, four capsules once) each for 16 weeks. Efficacy and safety biomarkers were measured before and after intervention. Results After 16 weeks of intervention, the group administered with NAOs had statistically significant decreases in visceral fat area and visceral-subcutaneous fat area ratio compared to the placebo group. The NAOs group suppressed the increase in weight and BMI compared to the placebo group, which was significant between groups. High-density lipoprotein- cholesterol was increased in the group administered with NAOs, which showed a significant trend compared to the placebo group. Clinical changes were not observed for any safety biomarkers. Conclusions These results suggest that NAOs have a beneficial effect on obesity. Thus, NAOs could be used as an anti-obesity supplement without side effects. Trial registration cris.nih.go.kr: (KCT0006640, 07/10/2021)..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC complementary and alternative medicine - 23(2023), 1 vom: 19. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baek, Hyang-Im [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Body weight |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12906-023-04206-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053464079 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053464079 | ||
| 003 | DE-627 | ||
| 005 | 20231120064740.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231020s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12906-023-04206-2 |2 doi | |
| 035 | |a (DE-627)SPR053464079 | ||
| 035 | |a (SPR)s12906-023-04206-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baek, Hyang-Im |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-obesity effect of Neoagaro-oligosaccharides with overweight and obese subjects: a 16-week, randomized, double-blind, placebo-controlled clinical trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background This trial aimed to evaluate the anti-obesity effects and safety of Neoagaro-oligosaccharides (NAOs) in humans in a 16 week, randomized, double-blind, placebo-controlled clinical trial. Methods One hundred overweight or obese subjects with a body mass index of 23 to 34.9 kg/$ m^{2} $ and a percent body fat of > 25% for males or > 30% for females were enrolled. NAOs or placebo products were administered at 3 g (twice a day, four capsules once) each for 16 weeks. Efficacy and safety biomarkers were measured before and after intervention. Results After 16 weeks of intervention, the group administered with NAOs had statistically significant decreases in visceral fat area and visceral-subcutaneous fat area ratio compared to the placebo group. The NAOs group suppressed the increase in weight and BMI compared to the placebo group, which was significant between groups. High-density lipoprotein- cholesterol was increased in the group administered with NAOs, which showed a significant trend compared to the placebo group. Clinical changes were not observed for any safety biomarkers. Conclusions These results suggest that NAOs have a beneficial effect on obesity. Thus, NAOs could be used as an anti-obesity supplement without side effects. Trial registration cris.nih.go.kr: (KCT0006640, 07/10/2021). | ||
| 650 | 4 | |a Neoagaro-oligosaccharides |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Overweight |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Obesity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Visceral fat |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Body weight |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Clinical trial |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ha, Ki-Chan |4 aut | |
| 700 | 1 | |a Park, Yu Kyung |4 aut | |
| 700 | 1 | |a Lee, Je Hyeon |4 aut | |
| 700 | 1 | |a Kim, Eun Joo |4 aut | |
| 700 | 1 | |a Ko, Hye-Jeong |4 aut | |
| 700 | 1 | |a Joo, Jong Cheon |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC complementary and alternative medicine |d London : BioMed Central, 2001 |g 23(2023), 1 vom: 19. Okt. |w (DE-627)SPR028106679 |w (DE-600)2050429-9 |x 1472-6882 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:19 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12906-023-04206-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 19 |c 10 | ||